Karuna Therapeutics - KRTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $259.47
  • Forecasted Upside: 9.56 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$236.82
▲ +6.84 (2.97%)

This chart shows the closing price for KRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Karuna Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRTX

Analyst Price Target is $259.47
▲ +9.56% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Karuna Therapeutics in the last 3 months. The average price target is $259.47, with a high forecast of $330.00 and a low forecast of $176.00. The average price target represents a 9.56% upside from the last price of $236.82.

This chart shows the closing price for KRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 investment analysts is to buy stock in Karuna Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/4/2022Wells Fargo & CompanyLower TargetOverweight$264.00 ➝ $262.00Low
11/1/2022Loop CapitalInitiated CoverageBuy$288.00Low
9/29/2022Royal Bank of CanadaBoost Target$292.00 ➝ $293.00Low
9/13/2022Stifel NicolausBoost TargetBuy$260.00 ➝ $295.00Low
8/15/2022CitigroupBoost Target$280.00N/A
8/15/2022HC WainwrightBoost TargetBuy$160.00 ➝ $320.00Low
8/12/2022Royal Bank of CanadaBoost TargetOutperform$160.00 ➝ $292.00Low
8/12/2022GuggenheimBoost TargetBuy$200.00 ➝ $330.00Low
8/10/2022Wells Fargo & CompanyBoost TargetOverweight$186.00 ➝ $264.00Low
8/9/2022The Goldman Sachs GroupBoost TargetBuy$228.00 ➝ $278.00Low
8/9/2022MizuhoBoost TargetBuy$190.00 ➝ $276.00Low
8/9/2022Bank of AmericaBoost TargetBuy$160.00 ➝ $261.00Low
8/9/2022SVB LeerinkBoost TargetOutperform$170.00 ➝ $270.00Low
7/14/2022SVB LeerinkInitiated CoverageOutperform$170.00Low
6/28/2022JMP SecuritiesBoost TargetMarket Outperform$175.00 ➝ $190.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$202.00 ➝ $174.00Low
4/27/2022MizuhoBoost Target$178.00 ➝ $190.00High
3/31/2022Berenberg BankInitiated CoverageBuy$190.00High
3/8/2022Jefferies Financial GroupBoost TargetBuy$180.00 ➝ $183.00Medium
3/3/2022MizuhoLower TargetBuy$182.00 ➝ $178.00Medium
1/24/2022WedbushBoost TargetOutperform$167.00 ➝ $176.00High
11/8/2021OppenheimerBoost TargetOutperform$148.00 ➝ $175.00Low
11/5/2021MizuhoBoost TargetBuy$150.00 ➝ $182.00High
11/4/2021Stifel NicolausBoost TargetBuy$154.00 ➝ $185.00High
9/30/2021JPMorgan Chase & Co.Initiated CoverageOverweight$162.00High
8/30/2021CitigroupInitiated CoverageBuy$152.00Low
7/28/2021Jefferies Financial GroupInitiated CoverageBuy$158.00High
6/23/2021Royal Bank of CanadaBoost TargetOutperform$164.00 ➝ $173.00High
5/7/2021The Goldman Sachs GroupLower TargetBuy$192.00 ➝ $171.00Medium
4/26/2021HC WainwrightBoost TargetBuy$130.00 ➝ $160.00High
3/22/2021Bank of AmericaInitiated CoverageBuy$150.00High
3/4/2021MizuhoBoost TargetBuy$116.00 ➝ $150.00N/A
3/1/2021OppenheimerBoost TargetOutperform$135.00 ➝ $148.00Low
2/26/2021Maxim GroupReiterated RatingBuyLow
2/26/2021MizuhoBoost TargetBuy$116.00 ➝ $150.00High
2/26/2021JMP SecuritiesBoost TargetOutperform$122.00 ➝ $167.00High
2/9/2021Royal Bank of CanadaInitiated CoverageOutperform$160.00Low
1/5/2021William BlairReiterated RatingBuyN/A
12/17/2020OppenheimerInitiated CoverageBuy$135.00Medium
11/19/2020Maxim GroupInitiated CoverageBuy$150.00Medium
8/11/2020William BlairReiterated RatingBuyMedium
8/6/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $130.00Low
7/31/2020William BlairReiterated RatingBuyLow
7/29/2020HC WainwrightReiterated RatingBuyHigh
6/24/2020HC WainwrightReiterated RatingBuy$140.00High
6/24/2020OppenheimerBoost TargetPositive ➝ Outperform$125.00 ➝ $135.00Medium
6/23/2020MizuhoReiterated RatingBuy$116.00High
6/3/2020Stifel NicolausBoost TargetBuy$126.00 ➝ $135.00Low
6/2/2020WedbushBoost TargetOutperform$117.00 ➝ $126.00Low
6/1/2020The Goldman Sachs GroupBoost TargetBuy$115.00 ➝ $131.00Medium
5/28/2020HC WainwrightInitiated CoverageBuy$140.00Medium
5/8/2020MizuhoBoost TargetBuy$103.00 ➝ $116.00Medium
4/27/2020OppenheimerInitiated CoverageOutperform$125.00High
3/31/2020GuggenheimInitiated CoverageBuy$120.00Low
3/24/2020WedbushReiterated RatingOutperform$124.00High
3/24/2020MizuhoReiterated RatingBuy$120.00High
2/5/2020MizuhoInitiated CoverageBuy$120.00High
1/22/2020Wells Fargo & CompanyBoost TargetOverweight$106.00 ➝ $137.00Medium
1/9/2020JMP SecuritiesInitiated CoverageOutperform$122.00Medium
12/19/2019Stifel NicolausInitiated CoverageBuy$126.00High
12/12/2019William BlairInitiated CoverageOutperform$105.00High
11/21/2019WedbushBoost TargetPositive ➝ Outperform$38.00 ➝ $134.00High
11/18/2019The Goldman Sachs GroupBoost TargetBuy ➝ Positive$35.00 ➝ $109.00High
11/12/2019WedbushReiterated RatingBuy$38.00Low
8/9/2019WedbushReiterated RatingOutperform$38.00High
7/23/2019WedbushInitiated CoverageOutperform ➝ Outperform$38.00Medium
7/23/2019CitigroupInitiated CoverageBuy ➝ Buy$28.00High
7/23/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$29.00High
7/23/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$34.00High
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/7/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 5 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/5/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/4/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Karuna Therapeutics logo
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $236.82
Low: $229.00
High: $238.67

50 Day Range

MA: $220.71
Low: $203.44
High: $236.82

52 Week Range

Now: $236.82
Low: $92.26
High: $278.25

Volume

304,351 shs

Average Volume

270,324 shs

Market Capitalization

$8.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Karuna Therapeutics?

The following equities research analysts have issued reports on Karuna Therapeutics in the last year: Bank of America Co., Berenberg Bank, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Loop Capital, Mizuho, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for KRTX.

What is the current price target for Karuna Therapeutics?

15 Wall Street analysts have set twelve-month price targets for Karuna Therapeutics in the last year. Their average twelve-month price target is $259.47, suggesting a possible upside of 9.6%. Guggenheim has the highest price target set, predicting KRTX will reach $330.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $176.00 for Karuna Therapeutics in the next year.
View the latest price targets for KRTX.

What is the current consensus analyst rating for Karuna Therapeutics?

Karuna Therapeutics currently has 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KRTX will outperform the market and that investors should add to their positions of Karuna Therapeutics.
View the latest ratings for KRTX.

What other companies compete with Karuna Therapeutics?

How do I contact Karuna Therapeutics' investor relations team?

Karuna Therapeutics' physical mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company's listed phone number is (857) 449-2244 and its investor relations email address is [email protected] The official website for Karuna Therapeutics is karunatx.com. Learn More about contacing Karuna Therapeutics investor relations.